论文部分内容阅读
目的探讨bufalin-mPEG-PLGA-PLL-cRGD体内药物靶向分布规律,为大肠癌的临床治疗提供实验依据和方法。方法建立荷C26结肠癌裸鼠模型,并随机分为两组:Dir-bufalin-mPEG-PLGA-PLL纳米组和Dir-bufalin-mPEG-PLGA-PLL-cRGD纳米组,经尾静脉给药。药物注射后3、19h后采用活体成像系统测定裸鼠活体的荧光强度。结果注射纳米粒3、19h后,与Dir-bufalin-mPEG-PLGA-PLL纳米粒相比,注Dir-bufalin-mPEG-PLGA-PLL-cRGD纳米粒的荷瘤裸鼠肿瘤部位显示出较高的荧光强度。结论 Dir-bufalin-mPEG-PLGA-PLL-cRGD纳米粒能更有效地靶向大肠癌。本实验制备的载药纳米粒的体内荧光活体成像实验数据表明,该纳米粒有助于提高大肠癌的治疗效果。
OBJECTIVE: To study the distribution of drug targets in bufalin-mPEG-PLGA-PLL-cRGD in vivo and provide experimental evidence and methods for the clinical treatment of colorectal cancer. Methods The C26 colon cancer nude mice model was established and randomly divided into two groups: Dir-bufalin-mPEG-PLGA-PLL nano-group and Dir-bufalin-mPEG-PLGA-PLL-cRGD nano group. Fluorescence intensity of nude mice was measured by in vivo imaging system 3 and 19 hours after drug injection. Results Compared with Dir-bufalin-mPEG-PLGA-PLL nanoparticles, tumor-bearing nude mice bearing Dir-bufalin-mPEG-PLGA-PLL-cRGD nanoparticles showed higher The fluorescence intensity. Conclusion Dir-bufalin-mPEG-PLGA-PLL-cRGD nanoparticles can target colorectal cancer more effectively. Experimental in vivo fluorescent live imaging of drug-loaded nanoparticles prepared in this experiment shows that the nanoparticles can help to improve the therapeutic effect of colorectal cancer.